4Pickup JC, Crook MA. Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia, 1998, 41 ( 10 ) : 1241 - 1248.
5Pradhan AD, Manson JE, Nader Rifai N, et al. C reactive reactive protein, interleukin - 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001,286 (3) : 327 - 334.
6Taniguchi A, Nagasaka S, Fukushima M, et al. C - reactive protein and insulin resistance in non - obese Japanese type 2 diabetic patients. Metabolism, 2002,51(12) : 1578 - 1581.
7Pradhan AD, Manson JE, Rifai N, et al. C - reactive protein, interleukin 6,and risk of developing type 2 diabetes mellitus. JAMA, 2001,286(3) :327 - 334.
1Wolffrenbuttel BHR,Gomist R,Squatrito S,et al.Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients.Diabetic Med,2000,17:40-47.
2Pradhan A D,Manson J E,Nader R,et al.C-reactive protein,interleukin-6,and risk of developing type 2 diabetes mellitus.JAMA,2001,286:327-334.
3Pickup JC,Crook MA.Is type Ⅱ diabetes mellitus a disease of innate immune system? Diabetologia,1998,41:1241-1248.
4Grigsby RJ,Dobrowsky RT.Inhibition of ceramide productionreverses TNF-induced insulin resistance.Biochem Biophys Res Commun,2001,287:1121 1124.
5Sjoholm A,Nystrom T. Endothelial inflammation in insulin resistance [J|. Lancet ,2005,365(9459) :610-612.
6Bahia L,Aguiar LG,villela N,ct al. Adipooctin ia aaaoetated with improvement of endothelial function after rosiglitazone treatment in non-diabetic non-diabetic individuals with metab-olicyndrome [J].Atheroscleosis ,2007,195( 1 ) : 138-146.
7Bennett SMA,Agrawal A,Elashat H,et al. Rosiglitazone improves in- suIinsensitivity,glucose tolerance and ambulatory blood pressure in sub- jects with impaired gluco tolerance [J]. Diabetic Medicine,2004,21 (5) : 415-422.
